Alnylam has shared data from a phase 3 trial of its near-approval kidney disease drug lumasiran in children as young as three months. The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.
Earlier this year, Alnylam filed for FDA approval of lumasiran on the strength of data linking it to a 65% drop in urinary oxalate in people with primary hyperoxaluria type 1 (PH1) aged six years and up. Last month, Alnylam followed up with news that lumasiran drove a “clinically significant” decline in urinary oxalate in children aged three to 72 months but held off on publishing the data.
